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Abstract
Introduction: Acute kidney injury is a widespread complication in hospitalized patients, with a high mortality rate and 
long-term complications affecting prognosis and quality of life and with high human and financial costs. In addition, to 
date, no clear algorithm for the prevention of this type of damage has been developed.
Materials and methods: The research was carried out on male Wistar rats. A 40-minute renal ischemia-reperfusion 
model was used to model acute kidney injury. Further, the renoprotective properties of carbamylated darbepoetin, 
udenafil and their combination were assessed based on the analysis of the biochemical studies’ results, dynamics of 
the renal status and the renal microvasculature, and the pathomorphological picture. A series of experiments was also 
carried out to assess the contribution of adenosine triphosphate-dependent potassium channels and nuclear factor kappa 
B to the renoprotective properties of the said agents.
Results and discussion: Prophylactic administration of carbamylated darbepoetin at a dose of 50 µg/kg and udenafil 
at a dose of 8.7 mg/kg led to a statistically significant decrease in creatinine and blood urea nitrogen, an increase in 
glomerular filtration rate with a simultaneous decrease in fractional excretion of sodium, as well as an increase in the 
level of microcirculation in the kidneys and a decrease in the severity of damage according to the data of a pathomor-
phological examination at all time points of the experiment. A higher efficiency of correcting ischemic and reperfusion 
renal injuries was observed when using a combination of the said pharmacological agents. A series of experiments with 
glibenclamide demonstrated that its preliminary administration levels the renoprotective properties of carbamylated 
darbepoetin and udenafil. The ability of the studied pharmacological agents to reduce lipopolysaccharide-induced ex-
pression of nuclear factor kappa B in mononuclear cells was also demonstrated. The results of the research suggest that 
the renoprotective effects of carbamylated darbepoetin, udenafil, and their combination are realized through ATP-de-
pendent potassium channels and nuclear factor kappa B.
Conclusion: Pharmacological preconditioning with carbamylated darbepoetin and udenafil reduces the severity of 
acute kidney injury induced by ischemia-reperfusion.
Copyright Kostina DA et al. This is an open access article distributed under the terms of  the Creative Commons Attribution License (CC-BY 4.0), which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
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Introduction
Acute kidney injury (AKI) is one of the pressing interdis-
ciplinary problems. According to international and nati-
onal recommendations, acute kidney injury is a pathop-
hysiological syndrome of acute kidney damage, which 
has a staged course from minimal changes in the renal 
function to its complete loss (KDIGO 2012).
Ischemic and reperfusion injuries are among the most 
important causes of acute kidney injury in various clinical 
situations (Basile et al. 2012, Makris and Spanou 2016, 
Dube et al. 2017). They are an independent risk factor for 
morbidity and mortality in vascular surgery, organ-pre-
serving kidney surgery, transplantation and cardiac sur-
gery (Dryazhenkov et al. 2013, Abu Jawdeh and Govil 
2017, An et al. 2017, Moore et al. 2018). In addition to its 
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high prevalence, acute kidney injury has become one of 
the major public health problems with high human and fi-
nancial costs, second only to the costs of treating patients 
with sepsis (Silver et al. 2017).
Currently, there is no generally accepted concept of kid-
ney protection from ischemic and reperfusion injuries. Both 
the KDIGO international recommendations and the Russi-
an clinical guidelines to detect and treat AKI include pre-
ventive measures aimed at maintaining an adequate level 
of circulating blood volume and hemodynamics, glycemic 
control and nutritional support (KDIGO 2012). One of the 
possible ways to prevent ischemic and reperfusion kidney 
damage is to expand the “time window” in order to reduce 
the severity of kidney damage. In this regard, one of the 
promising areas of renoprotective therapy for ischemic-re-
perfusion injuries is pharmacological pre- and post-con-
ditioning. Currently, of all types of preconditioning, phar-
macological preconditioning is preferred due to its higher 
efficiency and ease of implementation (Danilenko 2015).
One of the most studied pharmacotherapeutic agents 
with preconditioning properties is the glycoprotein hor-
mone erythropoietin (EPO) (Kaplin et al. 2013, Kolesnik 
et al. 2015, Shabelnikova 2016). EPO exerts its hemato-
poietic properties through its connection with the homo-
dimeric erythropoietin receptor (EPOR) on the precursors 
of the erythroid lineage in the bone marrow, accelerating 
the processes of erythropoiesis and increasing the number 
of mature erythrocytes (Watowich 2011, Kuhrt and Wo-
jchowski 2015, Bhoopalan et al. 2020). However, there 
is also a heterodimeric erythropoietin complex EPOR/
βCR, which consists of EPOR in combination with the 
ubiquitous β-common receptor (Brines et al. 2004, Rive-
ra-Cervantes et al. 2019, Vázquez-Méndez et al. 2020). 
Implementation of the cytoprotective properties of EPO 
in various models of ischemia-reperfusion is associated 
primarily with the activation of signaling cascades trigge-
red by a short contact of erythropoietin with this receptor 
complex (Brines and Cerami 2008, Collino et al. 2015). 
Renoprotective properties of erythropoietin were confir-
med not only in experimental, but also in clinical studies: 
for example, its preliminary administration in patients 
before performing coronary artery bypass graft surgery 
led to a decrease in the severity of acute kidney injury 
(Moore et al. 2011, Tasanarong et al. 2013). However, 
there are a number of factors that limit the use of erythro-
poietin as a cytoprotective agent: firstly, erythropoietin 
has a high affinity for classical homodimeric erythropoie-
tin receptors and a significantly lower affinity for EPOR/
βCR (Brines and Cerami 2008, Kebschull et al. 2017, 
Zubareva et al. 2019), responsible for the cytoprotective 
effects. Secondly, the use of high doses of erythropoietin 
entails an increased risk of side effects, such as impaired 
hemostasis with an increased risk of thrombus formation 
and arterial hypertension (Agarwal 2018, Zubareva et al. 
2019), which also adversely affects the erythropoietin ef-
ficacy as a preconditioning agent.
The main pathogenetic links of acute kidney injury 
are acute tubular necrosis (Basile et al. 2012, Makris et 
al. 2016), endothelial dysfunction (Bonventre and Yang 
2011, Sedaghat et al. 2019), inflammation (Bonventre and 
Yang 2011, Han and Lee 2019), and mitochondrial dys-
function (Bhargava and Schnellmann 2017). Thus, for the 
successful prevention of AKI, it is necessary to search for 
pharmacological agents with cyto-, endothelioprotective 
and anti-inflammatory properties. Some of these repre-
sentatives are new derivatives of erythropoietin with high 
affinity for the heterodimeric receptor complex EPOR/
βCR and phosphodiesterase (PDE) type 5 inhibitors.
Darbepoietin is a hyperglycosylated variant of re-
combinant human erythropoietin with three times longer 
half-life period. Darbepoietin has also shown to be as ef-
fective a neuroprotective agent as erythropoietin (Reznik-
ov et al. 2017). One of the ways to modify the erythro-
poietin molecule in order to potentiate the cytoprotective 
properties is carbamylation (Reznikov et al. 2017, Diao et 
al. 2019). At the same time, a number of studies confirm 
that carbamylated darbepoetin has neuro- (Tverskoi et al. 
2018, Shirokova 2019), retino- (Peresypkina et al. 2018), 
and cardioprotective effects (Kolesnichenko et al. 2019), 
in the absence of erythropoietic properties. Thus, combi-
nation of cytoprotective and endotheliotropic properties 
of carbamylated erythropoietin derivatives makes the de-
rivatives promising agents for the correction of ischemic 
and reperfusion renal injuries.
On the other hand, microcirculation disorders and 
endothelial dysfunction play an important role in the 
development of ischemic and reperfusion injuries (Bon-
ventre and Yang 2011, Basile et al. 2012, Sedaghat et 
al. 2019). Previously, it was demonstrated that phospho-
diesterase inhibitors have preconditioning properties in 
simulating ischemia-reperfusion in various organs and 
tissues, including kidney ischemia-reperfusion (Erol et 
al. 2015, Zahran et al. 2019, Nam et al. 2020). Udena-
fil is also a type 5 phosphodiesterase inhibitor used in 
the treatment of erectile dysfunction, but the distinctive 
feature of udenafil is its selectivity. The overwhelming 
concentration of udenafil is several times lower in rela-
tion to PDE-5 in comparison with PDE-1, PDE-2, PDE-
3, and PDE-4, and 10 times lower in comparison with 
PDE-6 (Doh et al. 2002, Cho and Paick 2014). Uden-
afil hardly inhibits PDE-11, which is localized in stria-
ted muscles, testes and lungs, which does not cause any 
cases of myalgia, lower back pains and manifestations 
of testicular toxicity when taken (the drug does not in-
hibit spermatogenesis) (Kouvelas et al. 2009, Zhao et 
al. 2011). According to several multicenter, randomized, 
double-blind, placebo-controlled trials, udenafil has a 
favorable safety profile (Cho and Paick 2014).
Thus, one of the promising directions for the preventi-
on and reduction of the severity of acute kidney injury is 
the study of the renoprotective effects of pharmacological 
agents and their combination under conditions of renal 
ischemia-reperfusion due to the activation of the hetero-
dimeric EPOR/βCR receptor complex by carbamylated 
darbepoetin and selective blockade of type 5 phospho-
diesterase with udenafil.
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Research aim
To evaluate efficiency of correcting ischemic and reper-
fusion renal injuries, using pharmacological preconditio-
ning with carbamylated darbepoetin and udenafil.
Materials and methods
Experimental work was conducted on 242 white adult 
male Wistar rats (weight 180–220 g). The experimental 
part of the study was carried out in accordance with GOST 
33044-2014 ”Principles of Good Laboratory Practice” the 
ethical principles of handling laboratory animals were ob-
served in accordance with the “European Convention for 
the Protection of Vertebral Animals Used for Experimen-
tal and Other Scientific Purposes. CETS No. 123”.
Simulation of bilateral renal ischemia-reperfusion
Experimental simulation was performed as follows: un-
der anesthesia (300 mg/kg of chloral hydrate, intraperi-
toneally), a midline laparotomy was performed, renal pe-
dicles were sequentially isolated, and atraumatic vascular 
clamps were applied, with 5 minutes apart. To choose the 
optimal time for the ischemic period, the animals were 
divided into 3 groups: group 1 – with a 30-minute ische-
mic period; group 2 – with a 40-minute ischemic period, 
group 3 – with a 60-minute ischemic period, the reperfu-
sion period – 72 hours. Further, the operating wound was 
sutured in layers. After choosing the optimal model of bi-
lateral renal ischemia-reperfusion, the severity of patho-
logical changes and the renoprotective properties of the 
drugs were assessed after 24 hours or 72 hours of reper-
fusion. In the group of sham-operated animals, a midline 
laparotomy was performed, and the wound was sutured 
40 minutes afterwards.
Renal microcirculation level
The microcirculation level was assessed using a MP100 
Biopac System (Biopac System Inc., USA), with the use 
of an LDF100C laser Doppler flowmetry (LDF) module 
and a TSD143 surface sensor. The level of microcircula-
tion was assessed within the first 5 minutes of reperfusi-
on, and then 24 or 72 hours later. Data registration and 
processing was carried out using AcqKnowledge version 
3.8.1. The values of the indicators were expressed in per-
fusion units (PU).
Laboratory methods for assessing the renal function
Concentrations of creatinine and blood urea nitrogen 
(BUN) in blood serum and urine were determined on a 
URIT800 Vet biochemical analyzer (URIT Medical Elec-
tronic Co., Ltd., China). The concentration of sodium ions 
in blood serum and urine was determined according to the 
standard technique on an automated biochemical analyzer 
AU480 (Beckman Coulter, Japan). To obtain urine sam-
ples, the animals were placed in metabolic cages with free 
access to water for 12 or 24 hours. Next, diuresis was 
measured, and samples were taken for further research.
The glomerular filtration rate (GFR) was calculated as 
follows (formula 1):
GFR
Urinecreatinine µmol l Urinevolume ml
Serumcrea
( )
tinine µmol l Collectiontime min( )
 (1)
Fractional excretion of sodium (FeNa) was calculated 
using the following formula (formula 2):
FeNa Urine sodium Serumcreatinine
Serumsodium Urinecreatinine (2)
Morphological methods for assessing changes in the 
kidneys
To conduct a pathomorphological study, the obtained 
material was fixed in a formalin solution, after which a 
portion of the renal tissue was removed, embedded in li-
quid paraffin, and sections were made. The obtained sec-
tions were stained with hematoxylin and eosin, by van 
Gieson’s and Mallory’s methods. Microscopy and photo-
graphy were carried out using a Leica CME microscope 
(Leica Microsystems, Germany) and a DCM-510 eyepie-
ce camera, followed by image processing with Future 
WinJoe software (Future Optics, USA). The morphome-
tric study included measuring the following parameters: 
the epithelial height of the nephron proximal and distal 
sections, the cross-sectional area of the renal corpuscle 
and the glomerulus.
Stimulation and determination of the expression of 
phosphorylated NF-κB in peripheral blood mononu-
clear cells
After sampling blood into vacuum tubes with lithium 
heparin, mononuclear cells (MNCs) were isolated on 
a Ficoll density gradient according to the standard me-
thod. The isolated MNCs were added to the plate wells 
in RPMI-1640 medium with 10% bovine embryo serum. 
In order to stimulate the expression of the investigated 
factor, lipopolysaccharide (LPS) from Escherichia coli 
was added to the cells. The studied drugs were added 
at the following final concentrations: carbamylated dar-
bepoetin – 100 ng/ml and udenafil – 400 ng/ml. Dexa-
methasone at a final concentration of 1×10-4 mol/L was 
used as a reference drug. Then the plate was placed for 
incubation at 37 °C in a humid atmosphere of 5% CO2 
for 48 hours. Then MNCs removed from the bottom 
of the well were transferred into test tubes, adding the 
supravital dye 7-aminoactinomycin, and then the tu-
bes were placed for incubation. Then MNCs were fixed 
using Fix & Perm Medium A for 15 min. After that, the 
cells were washed, and after removing the buffer, Fix & 
Perm Medium B medium and phosphate-buffered saline 
with rabbit antibodies to Phospho-NFkB p65 (Ser536) 
were added to the cell pellet, thoroughly resuspended 
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and incubated for 30 minutes. Then the cells were was-
hed, and Fix & Perm Medium B was added to the cell 
pellet with the addition of phosphate-buffered saline 
containing secondary Goat anti-Rabbit IgG (H+L) an-
tibodies labeled with allophycocyanin (APC). The cells 
with antibodies were thoroughly resuspended on a vor-
tex and incubated for 30 minutes. Thereafter, the cells 
were washed, resuspended in FACS Flow and analyzed 
on a FACSCanto II flow cytometer (BD, USA) with a 
488 nm blue laser. The data were collected using the BD 
FACSDiva v.8.0.2 program.
Research design. Choice of administration modes for 
pharmacological agents
The following experimental groups were included in the 
research design:
1. Intact animals;
2. Sham-operated animals (reperfusion period – 
24 hours);
3. Sham-operated animals (reperfusion period – 
72 hours);
4. Bilateral renal ischemia-reperfusion injury (isch-
emia – 30 minutes; reperfusion period – 72 hours);
5. Bilateral renal ischemia-reperfusion injury (isch-
emia – 40 minutes; reperfusion period – 72 hours);
6. Bilateral renal ischemia-reperfusion injury (isch-
emia – 60 minutes; reperfusion period – 72 hours);
7. Bilateral renal ischemia-reperfusion injury (isch-
emia – 40 minutes; reperfusion period – 24 hours);
8. Bilateral renal ischemia-reperfusion injury + carba-
mylated darbepoetin 50 µg/kg (ischemia – 40 min-
utes; reperfusion period – 24 hours);
9. Bilateral renal ischemia-reperfusion injury + carba-
mylated darbepoetin 50 µg/kg (ischemia – 40 min-
utes; reperfusion period – 72 hours);
10. Bilateral renal ischemia-reperfusion injury + carba-
mylated darbepoetin 50 µg/kg (ischemia – 40 min-
utes; reperfusion period – 24 hours);
11. Bilateral renal ischemia-reperfusion injury + carba-
mylated darbepoetin 50 µg/kg (ischemia – 40 min-
utes; reperfusion period – 72 hours);
12. Bilateral renal ischemia-reperfusion injury + darbe-
poetin 0.45 µg/kg (ischemia – 40 minutes; reperfu-
sion period – 24 hours);
13. Bilateral renal ischemia-reperfusion injury + darbe-
poetin 0.45 µg/kg (ischemia – 40 minutes; reperfu-
sion period – 72 hours);
14. Bilateral renal ischemia-reperfusion injury + ude-
nafil 8.7 mg/kg (ischemia – 40 minutes; reperfusion 
period – 24 hours);
15. Bilateral renal ischemia-reperfusion injury + ude-
nafil 8.7 mg/kg (ischemia – 40 minutes; reperfusion 
period – 72 hours);
16. Bilateral renal ischemia-reperfusion injury + silde-
nafil 4.3 mg/kg (ischemia – 40 minutes; reperfusion 
period – 24 hours);
17. Bilateral renal ischemia-reperfusion injury + silde-
nafil 4.3 mg/kg (ischemia – 40 minutes; reperfusion 
period – 72 hours);
18. Bilateral renal ischemia-reperfusion injury + carba-
mylated darbepoetin 50 µg/kg + udenafil 8.7 mg/
kg (ischemia – 40 minutes; reperfusion period – 
24 hours);
19. Bilateral renal ischemia-reperfusion injury + carba-
mylated darbepoetin 50 µg/kg + udenafil 8.7 mg/
kg (ischemia – 40 minutes; reperfusion period – 
72 hours);
20. Bilateral renal ischemia-reperfusion injury + car-
bamylated darbepoetin 50 µg/kg + glibenclamide 
(ischemia – 40 minutes; reperfusion period – 
24 hours);
21. Bilateral renal ischemia-reperfusion injury + car-
bamylated darbepoetin 50 µg/kg + glibenclamide 
(ischemia – 40 minutes; reperfusion period – 
72 hours);
22. Bilateral renal ischemia-reperfusion injury + udena-
fil 8.7 mg/kg + glibenclamide (ischemia – 40 min-
utes; reperfusion period – 24 hours);
23. Bilateral renal ischemia-reperfusion injury + udena-
fil 8.7 mg/kg + glibenclamide (ischemia – 40 min-
utes; reperfusion period – 72 hours);
24. Intact group (for blood samples).
In order to study the preconditioning properties of car-
bamylated darbepoetin when modeling ischemia-reper-
fusion of the kidneys, an injection solution (Farmapark 
LLC, Russia) was used at doses of 50 μg/kg and 300 μg/
kg once subcutaneously in the withers area 24 hours 
before modeling ischemia. Udenafil (Zydena, Dong-A 
Pharmaceutical Co. Ltd., Korea) was administered at a 
dose of 8.7 mg/kg once intragastrically via a tube 60 mi-
nutes before modeling ischemia. Darbepoetin (Aranesp, 
Amgen Europe B.V., Netherlands) was administered at 
a dose of 0.45 μg/kg 24 hours before the induction of 
ischemia, subcutaneously at the withers. Sildenafil (Vi-
agra, Pfizer, USA) was injected at a dose of 4.3 mg/kg 
once intragastrically via a tube 60 minutes before ische-
mia simulation. Glibenclamide (Maninil, Berlin-Chemi 
AG, Germany) was administered intragastrically via a 
tube at a dose of 5 mg/kg 30 minutes before the admi-
nistration of the pharmacological agents (Shabelnikova 
2016). In the darbepoetin and carbamylated darbepoetin 
groups, additional glibenclamide was administered 24 
hours after the first administration.
Statistical processing of research results
Descriptive statistics methods were used for all the data: 
the data were tested for normal distribution using the Sha-
piro-Wilk test. In the case of a normal distribution, the 
mean (M) and standard error of the mean (m) were calcu-
lated. In cases of abnormal distribution, the median (Me), 
1 and 3 quartiles (Q1; Q3) were calculated. Intergroup 
differences were analyzed by parametric (Student’s t-test) 
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or nonparametric (Mann-Whitney, Kruskal-Wallis tests) 
methods, depending on the type of distribution. All the 
calculations were performed using the statistical software 
package Microsoft Excel 2010, SPSS Statistic.
Results and discussion
Selection of the optimal duration of renal ischemia 
and assessment of the development of acute kidney 
injury in the simulation of bilateral renal ischemia-re-
perfusion
The results of assessing the level of serum creatinine and 
the survival rate of the animals of different groups after 
72 hours of reperfusion are presented in Table 1.
The absence of significant differences between the 
group of intact and sham-operated animals testifies to the 
technically correct execution of the experimental model 
and allows using the group of sham-operated animals as a 
comparison group. In all the experimental groups, the level 
of serum creatinine was significantly different from that in 
the group of sham-operated animals; however, the most 
serious renal dysfunctions were observed in the group of 
40-minute and 60-minute bilateral ischemia. But when as-
sessing the survival rate of the animals, there was a ten-
dency to an increase in the mortality rate with an increase 
in the duration of the ischemic stimulus. Thus, a 40-minute 
bilateral renal ischemia-reperfusion model is preferred for 
assessing the nephroprotective properties of drugs.
Renoprotective effects of carbamylated darbepoetin 
in bilateral renal ischemia-reperfusion simulation
When the pathology was corrected with carbamylated 
darbepoetin at the doses of 50 μg/kg and 300 μg/kg after 
24 hours of reperfusion, the creatinine level did not sig-
nificantly differ from that in the group of sham-operated 
animals; however, due to the restoration of diuresis, GFR 
reached 0.29±0.02 ml/min and 0.31±0.01 ml/min, respec-
tively, surpassing the comparison drug in efficiency. After 
72 hours of reperfusion, the serum creatinine level de-
creased to 70.8±3.1 μmol/L and 69.9±2.57 μmol/L when 
50  μg/kg and 300 μg/kg of carbamylated darbepoetin 
were used, respectively, with a simultaneous increase in 
GFR to 0.33±0.04 ml/min and 0.35±0.05 ml/min (Fig. 1).
The BUN concentration, on the contrary, was a more 
sensitive criterion after 24 hours of reperfusion and 
amounted to 6.14±0.31 mmol/L and 6.26±0.23 mmol/L, 
with prophylactic administration of 50 μg/kg and 300 μg/
kg of carbamylated darbepoetin. Another positive effect 
of carbamylated darbepoetin was its ability to improve 
the functional state of the renal tubular apparatus, which 
was indirectly evidenced by a decrease in fractional so-
dium excretion to 1.02±0.05% and 1.31±0.11% after 24 
and 72 hours of reperfusion, respectively, when using 
doses of 50 μg/kg (Fig. 1).
Prophylactic administration of carbamylated darbe-
poetin led to a decrease in the severity of microcirculatory 
disorders initiated by ischemia-reperfusion, manifested in 
recovery to 738.9±26.77 PU and 696±23.18 PU after 24 
and 72 hours of reperfusion, respectively, exceeding the 
efficiency of the reference drug. Similar dynamics was 
observed when using a dose of 300 μg/kg (Table 2).
With a pathomorphological examination, there is an 
improvement in the picture both in the tubular and in the 
glomerular apparatus of the kidneys (Fig. 2).
These data are confirmed by the morphometric data: 
epithelial height of the proximal renal tubules increases to 
a level comparable to that of sham-operated animals with 
a simultaneous increase in the renal glomerulus area after 
72 hours of reperfusion (Fig. 3).
Renoprotective effects of udenafil in modelling bilate-
ral renal ischemia-reperfusion
Prevention of ischemic and reperfusion renal injuries 
be means of udenafil led to a similar trend in the chan-
ge in biochemical parameters: the level of creatinine was 
59.5±1.41 μmol/L, and BUN – 6.95±0.25 mmol/L, which 
exceeded the effects of sildenafil after 24 hours of reper-
fusion (Fig. 4).
Table 1. Assessment of the Level of Serum Creatinine and Survival Rate of Animals with Different Duration of Renal Ischemia 
After 72 Hours of Reperfusion (n = 10).
Experimental groups Serum creatinine level, µmol/L Survival rate, %
Intact 56.9±1.63 100
Sham-operated 59.5±3.28 100
Bilateral renal ischemia-reperfusion injury, ischemia 30 min 76.9±4.67a 100
Bilateral renal ischemia-reperfusion injury, ischemia 40 min 136.8±7.02a 100
Bilateral renal ischemia-reperfusion injury, ischemia 60 min 203.7±6.68a 60
Note: a – p<0.05 in comparison with the group of sham-operated animals.
Table 2. Assessment of Microcirculation by Laser Doppler Flowmetry (PE) After 5 Minutes, 24 Hours and 72 Hours of Reperfusion 
Against the Background of Prophylactic Use of Carbamylated Darbepoetin (M±m; n = 10).
Experimental groups 5 minutes 24 hours 72 hours
Sham-operated 904.5±60.43 870.5±96.18 859±67.98
Renal ischemia-reperfusion 209±24.42a 418.1±46.02a 315.5 ±13.67a
Renal ischemia-reperfusion + darbepoetin 483.8±19.21a, b 686±27.39a, b 555.2±25.46a, b
Renal ischemia-reperfusion + carbamylated darbepoetin 50 µg/kg 667.9±40.34a, b 738.9±26.77b 696±23.18a, b
Renal ischemia-reperfusion + carbamylated darbepoetin 300 µg/kg 679.1±47.45a, b 749.8±32.19b 700.2±21.74a, b
Note: a – p<0.05 in comparison with the group of sham-operated animals; b – p<0.05 in comparison with the renal ischemia-reperfusion group.
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Figure 1. Effect of carbamylated darbepoetin at doses of 50 μg/kg and 300 μg/kg on serum creatinine concentration (A, B); glomer-
ular filtration rate (C, D); blood urea nitrogen concentration (E, F) and fractional sodium excretion (G, H) after 24 hours and 72 
hours of reperfusion. Note: sham – sham-operated animals; IR – renal ischemia-reperfusion; DE – darbepoetin; CDE 50 – carbamy-
lated darbepoetin (dose of 50 μg/kg); CDE 300 – carbamylated darbepoetin (dose of 300 μg/kg); a – p<0.05 in comparison with the 
group of sham-operated animals; b – p<0.05 in comparison with the renal ischemia-reperfusion group; * – p<0.05.
On the third day of the experiment, preliminary adminis-
tration of udenafil at a dose of 8.7 mg/kg led to a decrease 
in the level of serum creatinine to 72.4±2.28 μmol/L, and 
BUN – to 6.44±0.26 mmol/L. An increase in the glomerular 
filtration rate to 0.25±0.02 ml/min and 0.28±0.02 ml/min 
on the first and third days of the experiment, respectively, 
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Figure 2. Micrograph of the cortical substance (A) and tubular structures of the kidney (B) after 72 hours of reperfusion against the back-
ground of prophylactic use of carbamylated darbepoetin at a dose 50 μg/kg (stained with hematoxylin-eosin, magnification of ×400). 
Note: A large number of unchanged renal corpuscles are detected in the renal cortex. There are no signs of interstitial edema. There are 
single shrunken glomeruli. The proximal tubules with an indefinite diffuse lumen are formed with epithelial cells with a well-defined 
brush border on the apical surface. In the distal tubules, the lumen is well defined, the intercellular contacts are preserved. Locally, areas 
with dilated tubules and obturation of the lumen by dead epithelial cell pellet detached from the basement membrane are visualized.
Figure 3. Effect of carbamylated darbepoetin (50 μg/kg and 300 μg/kg) on the renal corpuscle area (A), renal glomerulus area (B), 
the epithelial height of the proximal renal tubules (C), the epithelial height of the distal renal tubules (D) after 24 and 72 hours of 
reperfusion. Note: sham – sham-operated animals; IR – renal ischemia-reperfusion; DE – darbepoetin; CDE 50 – carbamylated 
darbepoetin (dose of 50 μg/kg); CDE 300 – carbamylated darbepoetin (dose of 300 μg/kg); a – p<0.05 in comparison with the group 
of sham-operated animals; b – p<0.05 in comparison with the renal ischemia-reperfusion group; * – p<0.05.
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Figure 4. Effect of udenafil at a dose 8.7 mg/kg on serum creatinine concentration (A, B); glomerular filtration rate (C, D); blood urea 
nitrogen concentration (E, F) and fractional sodium excretion (G, H) after 24 hours and 72 hours of reperfusion. Note: sham – sham-op-
erated animals; IR – renal ischemia-reperfusion; Sild – sildenafil (dose of 4.3 mg/kg); Uden – udenafil (dose of 8.7 mg/kg); a – p<0.05 in 
comparison with the group of sham-operated animals; b – p<0.05 in comparison with the renal ischemia-reperfusion group; * – p<0.05.
also confirmed the renoprotective effects of udenafil. The 
FeNa values below 2% were also recorded only in the 
group of laboratory animals with prophylactic use of uden-
afil (1.21±0.05% and 1.57±0.08% after 24 and 72 hours of 
reperfusion), which indicates a higher efficacy of an uden-
afil therapy compared with a sildenafil therapy.
Udenafil also contributed to the restoration of the mi-
crocirculation level to 619.2±27.91 PU, 701.6±34.83 PU, 
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664.4±22.65 PU after 5 minutes, 24 hours, and 72 hours 
of reperfusion, respectively, which were statistically 
significantly different from the indicators in the control 
group and in the sham-operated rats (p<0.05). On the 
other hand, udenafil was superior to the reference drug 
sildenafil in terms of the efficacy of correction of micro-
circulatory disorders (Table 3).
A pathomorphological examination also showed a decre-
ase in the severity of tubular and glomerular injuries (Fig. 5).
This was confirmed by the morphometric data: epit-
helial height of the proximal renal tubules increased 
to 9.36±0.13 μm, with a simultaneous increase in the 
renal glomerulus area after 72 hours of reperfusion to 
4813.04±110.21 μm2 after prophylactic administration of 
udenafil versus 4487.13±87.09 μm2 – after administration 
of sildenafil (Fig. 6).
Renoprotective effects of the combination of carba-
mylated darbepoetin and udenafil in the simulation of 
bilateral renal ischemia-reperfusion
A combined therapy with carbamylated darbepoetin at a 
dose of 50 μg/kg and udenafil at a dose of 8.7 mg/kg was 
more effective and was characterized by a decrease in the 
level of BUN to 5.78±0.17 mmol/L, reaching the parame-
ters of the group of sham-operated animals with similar 
values of serum creatinine (56.8±1.23 μmol/L) after 24 
hours of reperfusion. After 72 hours of reperfusion, a si-
milar dynamics was observed: the efficiency of the com-
bined pharmacotherapy exceeded the monotherapy mo-
des, reaching the parameters of sham-operated animals: a 
decrease in the concentration of serum creatinine reached 
64.7±1.59 μmol/L, and BUN – to 6.12±0.23 mmol/L.
The glomerular filtration rate noticeably increased 
with the combined administration of carbamylated dar-
bepoetin and udenafil: up to 0.39±0.03 ml/min and 
0.43±0.02 ml/min on Days 1 and 3 of the experiment, 
respectively, statistically significantly exceeding the effi-
ciency of monotherapy modes with the indicated pharma-
cological agents (p<0.05), without reaching, however, the 
indicators of sham-operated animals.
The dynamics of fractional sodium excretion was si-
milar: it decreased to 0.8±0.02% and 0.78±0.05% after 
24 hours and 72 hours of reperfusion, respectively. Despi-
te the statistically significant differences from the group 
of sham-operated animals, the absence of oliguria in this 
Table 3. Assessment of Microcirculation by Laser Doppler Flowmetry (PE) After 5 Minutes, 24 Hours and 72 Hours of Reperfusion 
Against the Background of Prophylactic Use of Udenafil (M±m; n = 10).
Experimental groups 5 minutes 24 hours 72 hours
Sham-operated 904.5±60.43 870.5±96.18 859±67.98
Renal ischemia-reperfusion 209±24.42a 418.1±46.02a 315.5 ±13.67a
Renal ischemia-reperfusion + sildenafil 447.5±28.65a, b 691±16.67a, b 504.5±21.38a, b
Renal ischemia-reperfusion + udenafil 619.2±27.91a, b 701.6±34.83a, b 664.4±22.65a, b
Note: a – p<0.05 in comparison with the group of sham-operated animals; b – p<0.05 in comparison with the renal ischemia-reperfusion group.
Figure 5. Micrograph of the cortical substance (A) and tubular structures of the kidney (B) after 72 hours of reperfusion against 
the background of prophylactic use of udenafil at a dose 8.7 mg/kg (stained with hematoxylin-eosin, magnification of ×200). Note: 
There is detected moderate mesangial stromal edema. There are a few shrunken vascular glomeruli of the kidney. The brush border 
on the apical surface of the epithelial cells of some tubules is flattened; the cytoplasm is vacuolated and swollen. Reactive changes 
in the damaged epithelium of the tubules are observed: the brush border on the apical surface of some epithelial cells is flattened; 
the cytoplasm is vacuolated and swollen; some cells detach from the basement membrane and shed into the lumen of single tubules; 
some tubules are significantly expanded in diameter; there are small areas with necrotic tubules.
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Figure 6. Effect of udenafil on the renal corpuscle area (A), renal glomerulus area (B), the epithelial height of the proximal renal tu-
bules (C), the epithelial height of the distal renal tubules (D) after 24 hours and 72 hours of reperfusion. Note: sham – sham-operated 
animals; IR – renal ischemia-reperfusion; Sild – sildenafil (dose of 4.3 mg/kg); Uden – udenafil (dose of 8.7 mg/kg); a – p<0.05 in 
comparison with the group of sham-operated animals; b – p<0.05 in comparison with the renal ischemia-reperfusion group; * – p<0.05.
category of animals may indicate the normal function of 
the renal tubular apparatus.
Combined administration of carbamylated darbe-
poetin and udenafil led to a decrease in the severity of 
microcirculatory disorders initiated by ischemia-reper-
fusion, manifested in recovery to 764.3±48.46 PU and 
804.3±29.8 PU after 24 hours and 72 hours of reper-
fusion, respectively, exceeding the efficiency of mo-
notherapy modes with the indicated pharmacological 
agents (Table 4).
The pathological picture was close to that of sham-ope-
rated animals (Fig. 8).
This was also confirmed by the morphometric data 
of the tubular and glomerular apparatus of the kid-
neys (Fig. 9).
The role of ATP-dependent potassium channels in the 
realization of the renoprotective effects of carbamyla-
ted darbepoetin and udenafil in experimental renal 
ischemia-reperfusion
The preconditioning properties of carbamylated darbe-
poetin and udenafil, realized through ATP-dependent 
potassium channels, are confirmed by a series of experi-
ments with the preliminary introduction of glibenclami-
de. Thus, sequential administration of glibenclamide and 
carbamylated darbepoetin led to an increase in serum cre-
atinine after 72 hours of reperfusion to 90.5±3.16 μmol/L, 
and udenafil – to 93.7±2.11 μmol/L. The BUN concentra-
tion also significantly increased in all the experimental 
groups with pre-administration of glibenclamide, being 
Table 4. Assessment of Microcirculation by Laser Doppler Flowmetry (PE) After 5 Minutes, 24 Hours and 72 Hours of Reperfusion 
Against the Background of Prophylactic Use of Combination of Carbamylated Darbepoetin and Udenafil (M±m; n = 10).
Experimental groups 5 minutes 24 hours 72 hours
Sham-operated 904.5±60.43 870.5±96.18 859±67.98
Renal ischemia-reperfusion 209±24.42a 418.1±46.02a 315.5 ±13.67a
Renal ischemia-reperfusion + carbamylated darbepoetin 50 µg/kg 667.9±40.34a, b 738.9±26.77b 696±23.18a, b
Renal ischemia-reperfusion + udenafil 619.2±27.91a, b 701.6±34.83a, b 664.4±22.65a, b
Renal ischemia-reperfusion + carbamylated darbepoetin 50 µg/kg + udenafil 692.9±20.08a, b 764.3±48.46b 804.3±29.8b
Note: a – p<0.05 in comparison with the group of sham-operated animals; b – p<0.05 in comparison with the renal ischemia-reperfusion group.
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Figure 7. Effect of combined therapy with carbamylated darbepoetin at a dose of 50 μg/kg and udenafil at a dose of 8.7 mg/kg on 
serum creatinine concentration (A, B); glomerular filtration rate (C, D); blood urea nitrogen concentration (E, F) and fractional so-
dium excretion (G, H) after 24 hours and 72 hours of reperfusion. Note: sham – sham-operated animals; IR – renal ischemia-reper-
fusion; CDE 50 – carbamylated darbepoetin (dose of 50 μg/kg); Uden – udenafil (dose of 8.7 mg/kg); a – p<0.05 in comparison with 
the group of sham-operated animals; b – p<0.05 in comparison with the renal ischemia-reperfusion group; * – p<0.05.
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Figure 8. Micrograph of the cortical substance (A) and tubular structures (B) of the kidney 72 hours of reperfusion against the 
background of prophylactic use of combination of carbamylated darbepoetin at a dose 50 μg/kg and udenafil at a dose 8.7 mg/kg 
(stained with hematoxylin-eosin, magnification of ×400). Note: A large number of unchanged renal corpuscles are detected in the 
renal cortex. There are no signs of interstitial edema. The proximal tubules with an indefinite diffuse lumen are formed by prismatic 
epithelial cells with a well-defined brush border on the apical surface. In the distal tubules, the lumen is well defined, the intercel-
lular contacts are preserved. There are locally visualized areas with flattened cells with hyperchromic nuclei and figures of mitosis.
Figure 9. Effect of combined therapy with carbamylated darbepoetin at a dose of 50 μg/kg and udenafil at a dose of 8.7 mg/kg on the 
renal corpuscle area (A), renal glomerulus area (B), the epithelial height of the proximal renal tubules (C), the epithelial height of the 
distal renal tubules (D) after 24 hours and 72 hours of reperfusion. Note: sham – sham-operated animals; IR – renal ischemia-reper-
fusion; CDE 50 – carbamylated darbepoetin (dose of 50 μg/kg); Uden – udenafil (dose of 8.7 mg/kg); a – p<0.05 in comparison with 
the group of sham-operated animals; b – p<0.05 in comparison with the renal ischemia-reperfusion group; * – p<0.05.
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statistically significantly different from the values of the 
groups without glibenclamide (p<0.05).
The administration of glibenclamide neutralized the 
renoprotective properties of carbamylated darbepoetin 
and udenafil, which manifested itself in a statistically sig-
nificant increase in GFR on the first and third days of the 
experiment. So, after 24 hours of reperfusion, the bloc-
kade of K+ATP channels reduced the GFR level in the 
group of carbamylated darbepoetin to 0.21±0.02, udenafil 
–to 0.18±0.02, which was comparable with the indicators 
of the control group of animals. Preconditioning proper-
ties of carbamylated darbepoetin and udenafil were also 
confirmed by the dynamics of changes in the fractional 
excretion of sodium upon preliminary administration of 
glibenclamide (Fig. 10).
A blocker of ATP-dependent potassium channels also 
aggravated microcirculatory disorders against the back-
ground of correction with carbamylated darbepoetin at a 
dose of 50 μg/kg and udenafil at a dose of 8.7 mg/kg, 
which indicates a significant contribution of these chan-
nels to the implementation of the preconditioning proper-
ties of the studied drugs (Table 5).
There was also an increase in tubular and glomerular 
disorders according to the data of the pathomorphological 
examination (Fig. 11).
Role of nuclear factor kappa B in the realization of 
the renoprotective effects of carbamylated darbepoe-
tin and udenafil in experimental renal ischemia-reper-
fusion
When studying the effect of the pharmacological agents 
on the expression of the phosphorylated p65 subunit of 
nuclear factor kappa B, it was found that carbamylated 
darbepoetin and udenafil inhibit the lipopolysacchari-
de-stimulated activity of this factor, which is manife-
sted in a decrease in the expression of the active form of 
phospho-NF-κB p65 in MNCs to 74.14 (54.76; 103.51)% 
and 63.72 (46.61; 67.01)%, respectively (Fig. 12).
A universal mechanism, which to some extent is a 
component of acute kidney injury in various conditions, 
is ischemia and the subsequent reperfusion.
Erythropoietin was one of the first pharmacological 
agents used to prevent and treat AKI. However, the data 
obtained in clinical studies did not correspond to the dy-
namics reflected in animal studies (Elliott et al. 2017). 
The possible reasons for the low efficiency of erythro-
poietin in humans are its low affinity for the heterodimeric 
erythropoietin receptor, which implements cytoprotective 
effects, as well as the occurrence of side effects (prima-
rily, thrombosis) due to the use of high doses (Brines and 
Cerami 2008, Kebschull et al. 2017, Zubareva et al. 2019, 
Agarwal 2018). In this regard, an opportunity to study 
a new erythropoietin derivative with a high affinity for 
heterodimeric erythropoietin receptors and without ery-
thropoietic properties looked promising.
Preventive administration of carbamylated darbe-
poetin at the doses of 50 and 300 μg/kg 24 hours be-
fore ischemia led to a significant increase in GFR both 
after 24 hours and 72 hours of reperfusion, reaching 
0.33±0.04 ml/min and 0.35±0.02 ml/min by the third day 
of the experiment, respectively, with a decrease in serum 
creatinine of more than 1.9 times. A decrease both in the 
BUN concentration and in fractional sodium excretion 
was recorded at all time points of the experiment. There 
was also a statistically significant increase in the hemo-
dynamic parameters; however, the best indicators were 
achieved by the first day of the experiment, which was 
expressed in the restoration of the level of microcirculati-
on to 738.9±26.77 PU and 749.8±32.19 PU, when using 
50 μg/kg and 300 μg/kg of carbamylated darbepoetin, 
respectively, which corresponded to the level of micro-
circulation in the sham-operated animals. Also, both do-
ses of the investigated pharmacological agent improved 
the pathomorphological picture. The morphometric data 
supplemented the data of the pathomorphological picture.
A significant contribution of the nitric oxide system 
to the pathogenesis of acute kidney injury (Wang et al. 
2004, Maringer and Sims-Lucas 2016, Sedaghat et al. 
2019) and to the implementation of the preconditioning 
properties of pharmacological agents in ischemia-reper-
fusion (Park et al. 2003, Yamasowa et al. 2005) makes it 
possible to investigate drugs with pleiotropic properties, 
already available on the pharmaceutical market. Phosp-
hodiesterase-5 inhibitors are among these pharmacologi-
cal agents.
Preventive administration of the PDE-5 inhibitor, 
udenafil, at a dose of 8.7 mg/kg led to the implementation 
of its renoprotective effects under the conditions of ex-
perimental simulation of ischemia-reperfusion, expressed 
in a decrease in plasma concentrations of creatinine and 
BUN, an increase in the calculated GFR, a decrease in 
fractional sodium excretion, and restoration of the ren-
al microcirculation level, as well as an improvement in 
the pathomorphological picture and morphometric data 
after 24 and 72 hours of reperfusion, surpassing sildenafil 
in efficiency, however, not reaching the indicators of the 
sham-operated animals.
Table 5. Assessment of Microcirculation by Laser Doppler Flowmetry (PE) After 24 Hours and 72 Hours of Reperfusion in the 
Experimental Groups (M±m; n = 10).
Experimental groups 5 minutes 24 hours 72 hours
Sham-operated 904.5±60.43 870.5±96.18 859±67.98
Renal ischemia-reperfusion 209±24.42a 418.1±46.02a 315.5 ±13.67a
Renal ischemia-reperfusion + carbamylated darbepoetin. 50 µg/kg 667.9±40.34a, b 738.9±26.77b 696±23.18a, b
Renal ischemia-reperfusion + carbamylated darbepoetin. 50 µg/kg + glibenclamide 466.5±16.51a, b 624±27.28a, b 537.2±15.2a, b
Renal ischemia-reperfusion + udenafil 619.2±27.91a, b 701.6±34.83a, b 664.4±22.65a, b
Renal ischemia-reperfusion + udenafil + glibenclamide 469.7±15.03a, b 585.9±18.25a, b 490±21.49a, b
Note: a – p<0.05 in comparison with the group of sham-operated animals; b – p<0.05 in comparison with the renal ischemia-reperfusion group.
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Figure 10. Effect of preliminary administration of glibenclamide on serum creatinine concentration (A, B); glomerular filtration rate 
(C, D); blood urea nitrogen concentration (E, F) and fractional sodium excretion (G, H) after 24 hours and 72 hours of reperfusion. 
Note: sham – sham-operated animals; IR – renal ischemia-reperfusion; CDE 50 – carbamylated darbepoetin (50 μg/kg); Uden – 
udenafil (dose of 8.7 mg/kg); Glib – glibenclamide (dose of 5 mg/kg); a – p<0.05 in comparison with the group of sham-operated 
animals; b – p<0.05 in comparison with the renal ischemia-reperfusion group; * – p<0.05.
Failure to reach the target values against the back-
ground of a monotherapy with carbamylated darbepoetin 
and udenafil, primarily creatinine, necessitated to study 
the efficiency of a combined correction of ischemic- and 
reperfusion-induced kidney injuries. After 24 hours of 
reperfusion, preliminary administration of carbamylated 
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Figure 11. Effect of preliminary administration of glibenclamide on the renal corpuscle area (A), renal glomerulus area (B), the 
epithelial height of the proximal renal tubules (C), the epithelial height of the proximal renal tubules (D) after 24 and 72 hours of 
reperfusion. Note: sham – sham-operated animals; IR – renal ischemia-reperfusion; CDE 50 – carbamylated darbepoetin (50 μg/
kg); Uden – udenafil (dose of 8.7 mg/kg); Glib – glibenclamide (dose of 5 mg/kg); a – p<0.05 in comparison with the group of 
sham-operated animals; b – p<0.05 in comparison with the renal ischemia-reperfusion group; * – p<0.05.
Figure 12. Effect of carbamylated darbepoetin and udenafil on 
the expression of the phosphorylated p65 subunit of nuclear 
factor kappa B in MNCs. Note: LPS – lipopolysaccharide-stim-
ulated MNCs; Dex – dexamethasone; CDE – carbamylated dar-
bepoetin; Uden – udenafil; a – p<0.05 in comparison with the 
control group; b – p<0.05 in comparison with the lipopolysac-
charide-stimulated MNCs.
darbepoetin at a dose of 50 μg/kg and udenafil at a dose of 
8.7 mg/kg led to a significant increase in the GFR index 
to 0.39±0.03 ml/min, which was comparable to that of 
the sham-operated animals and exceeded the efficiency 
of monotherapy modes with these drugs. By Day 3, the 
concentration of creatinine decreases more than twofold, 
thus surpassing the modes of monotherapy with the in-
dicated pharmacological agents with a simultaneous in-
crease in GFR to 0.43±0.02 ml/min. BUN concentrations 
decreased in all time periods of the experiment against 
the background of preventive administration of carba-
mylated darbepoetin and udenafil. FeNa also decreased 
by 2.6 and 12 times on the first and third days, respective-
ly. Renal hemodynamic disorders were also successfully 
neutralized by the combination under study: after 24 and 
72 hours of reperfusion, the level of microcirculation was 
764.3±48.46 PU and 804.3±29.8 PU, respectively, which 
corresponded to the parameters of the sham-operated ani-
mals. The pathological picture was close to that of the 
sham-operated animals. The next series of experiments 
revealed the preconditioning properties of carbamyla-
ted darbepoetin and udenafil by means of preliminary 
blockade of ATP-dependent potassium channels through 
preliminary administration of glibenclamide at a dose of 
5 mg/kg: this led to the elimination of the positive effects 
of carbamylated darbepoetin and udenafil, presumably 
due to blockade of ATP-dependent potassium channels.
Inflammation is an integral part of ischemic and sub-
sequent reperfusion injury. One of the regulators of such 
inflammation is the nuclear factor kappa B system. Most 
of the genes that are under the transcriptional control of 
NF-κB encode the synthesis of biologically active sub-
stances involved in the immune response and inflamma-
tory reactions (Johnson et al. 2017, Kezić et al. 2017). 
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A series of experiments to study the inhibitory activity 
of udenafil and carbamylated darbepoetin against nuclear 
factor kappa B on rat mononuclear cells demonstrated a 
decrease in the expression of the active form of phospho-
NF-κB p65 to 74.14 (54.76; 103.51)% and 63.72 (46.61; 
67.01)% in the groups of carbamylated darbepoetin and 
udenafil, respectively, which is evidence of the realization 
of the renoprotective properties of these pharmacological 
agents by means of anti-inflammatory action through the 
nuclear factor kappa B system.
Conclusion
The presented data demonstrate renoprotective proper-
ties of pharmacological preconditioning with carba-
mylated darbepoetin and udenafil under the conditions 
of simulating bilateral 40-minute ischemia-reperfusion 
of rat kidneys.
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